UXI4.F - Cyclacel Pharmaceuticals, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.5940
+0.0220 (+3.85%)
As of 09:19AM CEST. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.5720
Open0.5940
Bid0.5920 x N/A
Ask0.6480 x N/A
Day's Range0.5940 - 0.5940
52 Week Range0.4220 - 1.9490
Volume400
Avg. Volume6
Market Cap8.064M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-1.8600
Earnings DateAug 08, 2023 - Aug 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for UXI4.F

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Insider Monkey

      Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2023 Earnings Call Transcript

      Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2023 Earnings Call Transcript May 11, 2023 Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.66. Operator: Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. After today’s call […]

    • Thomson Reuters StreetEvents

      Q1 2023 Cyclacel Pharmaceuticals Inc Earnings Call

      Q1 2023 Cyclacel Pharmaceuticals Inc Earnings Call

    • GlobeNewswire

      Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

      - Key Catalysts ahead with multiple Value Generating Readouts -- Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib -- Advancing single-agent Efficacy with Differentiated Oral Plogosertib -- Adds to Balance Sheet with non-dilutive $4.7 million from R&D Tax Credit -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceu

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results

      BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thursday, May 11, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call: (800) 274-8461 / international

    • GlobeNewswire

      Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit

      BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received a payment of £3.9 million ($4.7 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government. The tax credit is for R&D costs incurred in the year ended December 31, 2022 and represen

    • Insider Monkey

      Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call Transcript

      Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call Transcript March 6, 2023 Operator: Good afternoon and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call and Webcast. Please note, today’s call is being recorded. I would now like to turn the call over to the company. Irina Koffler: Good afternoon, […]

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Participate in March Investor Conferences

      BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences. Oppenheimer 33rd Annual Healthcare Conference: Location:VirtualFormat:Fireside chat and one-on-one meetingsDate:March 13-15, 2023

    • Thomson Reuters StreetEvents

      Q4 2022 Cyclacel Pharmaceuticals Inc Earnings Call

      Q4 2022 Cyclacel Pharmaceuticals Inc Earnings Call

    • GlobeNewswire

      Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update

      - On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2023 and Report Interim data in 2H 2023 - - Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation - - Expect to Report Initial Data from Oral Plogosertib 140-101 Dose Escalation - - Management to Host Conference Call at 4:30 pm ET Today - BERKELEY HEIGHTS, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results

      BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2022 financial results on Monday, March 6, 2023. The Company will host a conference call at 4:30pm ET on the same day. Conference call information: Participant Toll-Free Number: 800-245-3047 Primary Participant Direct/

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference

      BERKELEY HEIGHTS, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present an overview of Cyclacel’s business and clinical programs at the BIO CEO & Investor Conference taking place at the New York Marriott Marquis Times Square on Febru

    • GlobeNewswire

      Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

      – Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting Key Data Readouts for Oral Fadraciclib in 2023 – – Expecting Preliminary Safety and Efficacy Update for Oral Plogosertib (formerly CYC140) in Advanced Solid Tumors in 1H 2023 – – Existing Cash Until End of 2023 Support Multiple Data Readouts – BERKELEY HEIGHTS, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) --

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023

      BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events are taking place January 9-11, 2023

    • GlobeNewswire

      Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

      - Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma - - Two Partial Responses in Lymphoma and 11 Stable Diseases in Advanced Solid Tumors - - Expect to Determine Recommended Phase 2 Dose for Oral Fadraciclib and Start Phase 2 in 1Q 2023 - - Encouraging Activity in First Dose Level of Oral CYC140, PLK1 Inhibitor, with Durable Stable Disease in Two Patients with Ovarian and KRAS G12V mutated Non

    • Zacks

      Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release

      Wix's (WIX) Q3 performance is likely to have benefited from strong bookings growth and an improvement in the user base. Forex volatility and weakness in global macroeconomic conditions are likely to have acted as headwinds.

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results

      BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results on Wednesday, November 9, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day. Conference call information: US/Canada call: (800) 225-9448 / international ca

    • GlobeNewswire

      Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

      Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patientsBERKELEY HEIGHTS, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported today preliminary dose escalation data from its ongoing 065-101 Phase 1/2 clinical study of oral fadracicl

    • GlobeNewswire

      Cyclacel Hosting Research & Development Day

      -Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma- -Monday, October 31st @ 10 am ET- BERKELEY HEIGHTS, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will host a research and development day, featuring ke

    • GlobeNewswire

      Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

      - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma -BERKELEY HEIGHTS, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will present preliminary dose escalation data from its ongoing 065-101 Phase 1/2 clinical trial of oral fadra

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference

      BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann’s 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York. Event:Ladenburg Thalmann 2022 Healthcare ConferenceDate:Thursday, September 29, 2022Time/location:9:30am ET, Trac

    • GlobeNewswire

      Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

      - Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9 – - Company to host R&D day in fall of 2022 to highlight data updates for fadraciclib and CYC140 in solid tumor Phase 1/2 studies - Cash runway into 2H 2023 - - Conference call scheduled for August 10, 2022 at 4:30 pm ET - BERKELEY HEIGHTS, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.

    • GlobeNewswire

      Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

      BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results on Wednesday, August 10, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: US/Canada call: (800) 225-9448 / interna

    • Benzinga

      Cyclacel To Test Higher Doses Of Fadraciclib In Solid Tumor Patients

      Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is adding two dose levels in a protocol amendment to test higher doses of oral fadraciclib before determining the recommended Phase 2 dose anticipated in 2H of 2022, citing the absence of dose-limiting toxicities. Fifteen patients with advanced solid tumors and lymphomas were treated with oral fadraciclib at all five doses. In the first oral treatment cycle with fadraciclib, a cutaneous T cell lymphoma patient achieved partial response (PR). A patient

    • GlobeNewswire

      Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

      - Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of Target Engagement for CDK2 and CDK9 - - Early Anticancer Activity, Including Partial Response and Stable Disease with Tumor Shrinkage,Observed in Patients with Endometrial Cancer, Pancreatic Cancer and T Cell Lymphoma - - R&D Day Planned for Fall 2022 - BERKELEY HEIGHTS, N.J., June 30, 2022 (GLOBE NEWSWIR

    • GlobeNewswire

      Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors

      BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders. "We are very pleased to welcome Ken to our Board of Directors,” said Ch